The current role of chemotherapy in metastatic hormone-refractory prostate cancer

Daniel P. Petrylak, Matthew R. Smith, Michael A Carducci

Research output: Contribution to journalArticle

Abstract

Since the publication of the Southwest Oncology Group (SWOG) 99-16 and TAX 327 studies, which demonstrated a survival benefit for docetaxel-based therapy, clinicians for the first time have a therapy to offer men with metastatic prostate cancer that is not merely palliative in its effects. Phase 2 and phase 3 trials are now building on the findings of SWOG 99-16 and TAX 327 by evaluating the potential of combination taxane-based therapies, such as docetaxel plus high-dose calcitriol, docetaxel-estramustine-bevacizumab, and docetaxel-thalidomide. The optimal timing of docetaxel-based chemotherapy is still unknown, as there are no prospective clinical trial data to indicate whether earlier treatment (eg, at the time of prostate-specific antigen failure) is more or less effective than later treatment (eg, in metastatic and/or symptomatic disease).

Original languageEnglish (US)
Pages (from-to)3-8
Number of pages6
JournalUrology
Volume65
Issue number5 SUPPL.
DOIs
StatePublished - May 2005
Externally publishedYes

Fingerprint

docetaxel
Prostatic Neoplasms
Hormones
Drug Therapy
Estramustine
Therapeutics
Thalidomide
Calcitriol
Prostate-Specific Antigen
Publications
Clinical Trials
Survival

ASJC Scopus subject areas

  • Urology

Cite this

The current role of chemotherapy in metastatic hormone-refractory prostate cancer. / Petrylak, Daniel P.; Smith, Matthew R.; Carducci, Michael A.

In: Urology, Vol. 65, No. 5 SUPPL., 05.2005, p. 3-8.

Research output: Contribution to journalArticle

Petrylak, Daniel P. ; Smith, Matthew R. ; Carducci, Michael A. / The current role of chemotherapy in metastatic hormone-refractory prostate cancer. In: Urology. 2005 ; Vol. 65, No. 5 SUPPL. pp. 3-8.
@article{1e9652349a7a41379ce128ac57d92424,
title = "The current role of chemotherapy in metastatic hormone-refractory prostate cancer",
abstract = "Since the publication of the Southwest Oncology Group (SWOG) 99-16 and TAX 327 studies, which demonstrated a survival benefit for docetaxel-based therapy, clinicians for the first time have a therapy to offer men with metastatic prostate cancer that is not merely palliative in its effects. Phase 2 and phase 3 trials are now building on the findings of SWOG 99-16 and TAX 327 by evaluating the potential of combination taxane-based therapies, such as docetaxel plus high-dose calcitriol, docetaxel-estramustine-bevacizumab, and docetaxel-thalidomide. The optimal timing of docetaxel-based chemotherapy is still unknown, as there are no prospective clinical trial data to indicate whether earlier treatment (eg, at the time of prostate-specific antigen failure) is more or less effective than later treatment (eg, in metastatic and/or symptomatic disease).",
author = "Petrylak, {Daniel P.} and Smith, {Matthew R.} and Carducci, {Michael A}",
year = "2005",
month = "5",
doi = "10.1016/j.urology.2005.03.053",
language = "English (US)",
volume = "65",
pages = "3--8",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5 SUPPL.",

}

TY - JOUR

T1 - The current role of chemotherapy in metastatic hormone-refractory prostate cancer

AU - Petrylak, Daniel P.

AU - Smith, Matthew R.

AU - Carducci, Michael A

PY - 2005/5

Y1 - 2005/5

N2 - Since the publication of the Southwest Oncology Group (SWOG) 99-16 and TAX 327 studies, which demonstrated a survival benefit for docetaxel-based therapy, clinicians for the first time have a therapy to offer men with metastatic prostate cancer that is not merely palliative in its effects. Phase 2 and phase 3 trials are now building on the findings of SWOG 99-16 and TAX 327 by evaluating the potential of combination taxane-based therapies, such as docetaxel plus high-dose calcitriol, docetaxel-estramustine-bevacizumab, and docetaxel-thalidomide. The optimal timing of docetaxel-based chemotherapy is still unknown, as there are no prospective clinical trial data to indicate whether earlier treatment (eg, at the time of prostate-specific antigen failure) is more or less effective than later treatment (eg, in metastatic and/or symptomatic disease).

AB - Since the publication of the Southwest Oncology Group (SWOG) 99-16 and TAX 327 studies, which demonstrated a survival benefit for docetaxel-based therapy, clinicians for the first time have a therapy to offer men with metastatic prostate cancer that is not merely palliative in its effects. Phase 2 and phase 3 trials are now building on the findings of SWOG 99-16 and TAX 327 by evaluating the potential of combination taxane-based therapies, such as docetaxel plus high-dose calcitriol, docetaxel-estramustine-bevacizumab, and docetaxel-thalidomide. The optimal timing of docetaxel-based chemotherapy is still unknown, as there are no prospective clinical trial data to indicate whether earlier treatment (eg, at the time of prostate-specific antigen failure) is more or less effective than later treatment (eg, in metastatic and/or symptomatic disease).

UR - http://www.scopus.com/inward/record.url?scp=18844383164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844383164&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.03.053

DO - 10.1016/j.urology.2005.03.053

M3 - Article

VL - 65

SP - 3

EP - 8

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5 SUPPL.

ER -